Takeda Pharmaceutical Files 6-K

TL;DR

Takeda filed a 6-K on 6/26/24, confirming its Tokyo HQ.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on June 26, 2024, reporting as a foreign private issuer. The filing indicates Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.

Why It Matters

This filing serves as an update for investors regarding Takeda's status as a foreign private issuer, providing essential contact and location information.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.

Key Players & Entities

• Takeda Pharmaceutical Company Limited (company) — Filer
• 0001395064-24-000083 (filing_id) — Accession Number
• June 2024 (date) — Reporting Period
• 001-38757 (company_id) — Commission File Number
• 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan (address) — Principal Executive Offices

FAQ

Filing Documents

• form6k-1_062624.htm (6-K) — 21KB
• 0001395064-24-000083.txt ( ) — 22KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date June 26, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller TRANSLATION Please note that the following is an English translation of the original Japanese version, prepared only for the convenience of shareholders residing outside Japan. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail. June 26, 2024 To Our Shareholders Christophe Weber President and Representative Director Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome Chuo-ku, Osaka 540-8645, Japan Notice of Resolutions at the 148th Ordinary General Meeting of Shareholders Dear Shareholders We hereby report as follows on the matters reported on and the resolutions made at the 148th Ordinary General Meeting of Shareholders of the Company held today. Matters reported on 1. Business Report, Consolidated Financial Statements, and Unconsolidated Financial Statements for the 147th fiscal year (from April 1, 2023 to March 31, 2024) 2. Audit Reports on the Consolidated Financial Statements for the 147th fiscal year by the Accounting Auditor and the Audit and Supervisory Committee The contents of these documents were reported. Matters resolved First Proposal Appropriation of Surplus This item was approved as originally proposed. (The year-end dividend is 94 yen (JPY94.00) per share.) Second Proposal Election of Ten (10) Directors who are not Audit and Supervisory Committee Members As proposed, Christophe Weber, Andrew Plump, Masami Iijima, Ian Clark, Steven Gillis, John Maraganore, Michel Orsinger and Miki Tsusaka were re-elected, Milano Furuta and Emiko Higashi were newly elected, and all ten (10) Directors who are not Audit and Superv

View Full Filing

View this 6-K filing on SEC EDGAR